viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc presents at the Proactive One2One virtual investment forum

Christopher J. Moreau, CEO of Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) presents to investors at the Proactive One2One virtual investment forum. Algernon is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The company identifies drugs that are used to treat one condition but repurposes them for different treatments. Most recently the company is focusing its efforts on repurposing ifenprodil (NP-120) as a potential COVID-19 treatment. Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.27 CAD

Market: CSE
Market Cap: $37.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...


Algernon Pharmaceuticals looks to highly regarded UK company to conduct...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has chosen renowned contract research organization Hammersmith Medicines Research located in the UK to conduct their Phase 1 stroke program study using...

3 days, 2 hours ago

2 min read